172 - The First Proof-of-Concept Clinical Trial of an HIV-1 Allosteric Integrase Inhibitor, Pirmitegravir (STP0404)

Monday, October 20, 2025

1:57 PM - 2:09 PM US ET

Location: B401-B402

Co-Author(s)

Moti Ramgopal, MD, FACP, FIDSA (he/him/his)

Medical Director
Midway Immunology and Research Center
Fort Pierce, FL, United States
PB

Paul Benson, DO

HIV Specialist
Be Well Medical Center
Berkley, MI, United States
John C. Williamson, PharmD (he/him/his)

Associate Professor
Wake Forest School of Medicine
Winston-Salem, NC, United States
MB

Mezgebe Berhe, MD, MPH

Infectious Disease specialist
North Texas Infectious Diseases Consultants
Dallas, Texas, United States
PR

Peter Ruane, MD

Ruane Clinical Research, Los Angeles, CA, USA
Los Angeles, California, United States
BC

Beata Casanas, MD

Professor of Medicine
University of South Florida
Tampa, Florida, United States
ED

Edwin DeJesus, MD

Medical Director
Orlando Immunology Center, University of Central Florida College of Medicine
Orlando, FL, United States
CL

Christopher Lucasti, MD

South Jersey Infectious Disease
Somers Point, New Jersey, United States

Disclosure(s):

John C. Williamson, PharmD: F2G Ltd: Grant/Research Support; Locus Biosciences: Grant/Research Support; ST Pharm: Grant/Research Support